ArticleEuropean journal of drug metabolism and pharmacokinetics2021

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.

Sophia Liva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.